Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe

Published on Wednesday, 28 July 2010 11:27 Written by TradersHuddle Staff

NATICK, Massachusetts, July 28, 2010 /PRNewswire-FirstCall/ --

- Company Expands Market-leading Family of Neurovascular Stents

Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

The Neuroform EZ Stent System is engineered to provide flexibility and conformability, especially in tortuous brain anatomy. It employs Boston Scientific's proprietary Segmental(TM) Expansion technology, designed to enhance stent anchoring and stability. The product features the proven hybrid cell design of prior-generation Neuroform Stents while incorporating a simplified, single-operator delivery system intended to facilitate preparation, delivery and positioning of the stent.

The first Neuroform EZ Stent was implanted in the U.S. by Demetrius Lopes, M.D., of the Rush University Medical Center in Chicago, and the first European procedure was performed by Professor Laurent Spelle, M.D., Ph.D., at Foundation Rothschild Hospital, Beaujon School of Medicine in Paris.

"The Neuroform EZ Stent System performed well in a very challenging first procedure," said Dr. Lopes. "The smooth transfer of the stent into the catheter, combined with excellent support, stability and visibility, facilitated accurate stent placement."

"The improved delivery system of the Neuroform EZ Stent helped me to place the stent exactly where I planned," said Professor Spelle. "In my experience, Boston Scientific's new system is easier to use compared to its previous microdelivery system and should offer benefits for both physicians and patients."

"Boston Scientific is pleased to offer this new technology, which is designed to help physicians simplify these complex neurovascular procedures," said Mark Paul, President of Boston Scientific's Neurovascular Division. "The Neuroform EZ Stent System reinforces our commitment to providing advanced treatment options focused on improving patient care."

Boston Scientific will demonstrate its Neuroform EZ Stent System at the 7th Annual Society of NeuroInterventional Surgery (SNIS) Meeting, July 26 - 30 in Carlsbad, California.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, clinical outcomes and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:
    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

SOURCE Boston Scientific Corporation